Skip to content
Company Analysis

Cytosorbents Corporation CTSO

A comprehensive view of key metrics, scores, and financial health for Cytosorbents Corporation

Overview of Cytosorbents Corporation

CTSO NCM
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Micro Cap
Cytosorbents Corporation (CTSO), is a Micro Cap company, in the Medical Devices industry, last closed at $0.40, about 22.5% overvalued vs fair value, -63.3% 1Y return, ranked 638/1122 in sector.
USD 0.40
3.04%
(Delayed)
• Vol 90d: 64.1%
52-Week Range
Market Cap
$25.80M
Enterprise Value
$45.40M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Completeness: 82%
Confidence: 53%
Updated: Mar 8
Top Beats

Quick Facts

Website https://www.cytosorbents.com
HQ Princeton, NJ
Employees 149
Fiscal year Dec 31

Next Events

Earnings Aug 6 Estimated

Fair Value Snapshot

Bear Base Bull
$0
$0
$0
Current: $0.40 -23% vs base

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$35.6M
14.5%%
Gross Profit
$25.1M
14.5%%
Operating Income (GAAP)
$-16.8M
47.5%%
EBITDA
$-19.3M
30.9%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
70.6%
Excellent

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Cytosorbents Corporation's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
43
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
60
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 83% Coverage
Trade-Off Triangle Visualization A ternary plot showing CTSO's balance between Growth (36.5%), Profitability (29.2%), and Safety (34.3%). Growth 37% Safety 34% Profitability 29%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

51th percentile vs peers
52
Key Signals
Rev Growth YoY 14.5% 67p EPS Growth YoY 41.9% 63p Revenue CAGR 3Y -3.9% 20p Asset Growth YoY -10.5% 30p
Strengths
  • D/E Ratio in top 20% of peers (2.42, 92th percentile)
  • Debt/Assets in top 20% of peers (56.8%, 86th percentile)
  • Conservative leverage compared to industry peers
Risks

No significant risks identified for this axis.

Profitability

41th percentile vs peers
41
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

48th percentile vs peers
48
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Cytosorbents Corporation.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$0.31
- - -
-22.5% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000